Ivabradine vs Placebo: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.245	0.23	0.26	wilson	ClinicalTrials.gov
Risk in group 2	0.287	0.272	0.303	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	-0.0424	-0.0638	-0.0209	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	0.852	0.786	0.924	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	0.804	0.72	0.898	log	ClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Ivabradine than on Placebo	23.6	15.7	47.8	from the risk difference interval	ClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Ivabradine	Ivabradine: 2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.	793	3,241	OG000	ClinicalTrials.gov
Group 2	Placebo	Placebo: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.	937	3,264	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	PRIMARY	ClinicalTrials.gov
Title	Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.	ClinicalTrials.gov
Description	Number of patients having experienced the Primary Composite Endpoint.	ClinicalTrials.gov
Time frame	All over the study (up to 42 months).	ClinicalTrials.gov
Population		ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study	ClinicalTrials.gov
NCT number	NCT02441218	ClinicalTrials.gov
Phases	PHASE3	ClinicalTrials.gov
Conditions	Chronic Heart Failure	ClinicalTrials.gov
Interventions	Ivabradine, Placebo	ClinicalTrials.gov
Lead sponsor	Institut de Recherches Internationales Servier	ClinicalTrials.gov
Results first posted	2015-06-29	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT02441218?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.